Diseases of the Circulatory System, Essential Hypertension
Conditions
Brief summary
The study design was composed of 2 parts, 2-way crossover and multiple-dose. There are having 2 groups in each part that have divided period 1 and period 2, and wash-out period is 16 days between periods. Each group is taking Telmisartan (80mg) and/or Atorvastatin (80mg) once a day for 6 days.
Interventions
DRUGTelmisartan
DRUGAtorvastatin
Sponsors
Samil Pharmaceutical Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
19 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy male subjects between the ages of 19 and 55 years * Subjects who don't have congenital or chronic diseases and have no abnormal medical examination results within 3 years * Healthy Subjects (no clinically relevant findings in any of the investigations of the pre-examination) as judged by the investigator * Subjects who signed and dated in informed consent form indicating that the subject has decided to participate in the study after being informed of all pertinent aspects of the study * Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures
Exclusion criteria
* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (but excluding untreated, asymptomatic, seasonal allergies at time of dosing) * Any condition possibly affecting drug absorption, distribution, metabolism, and excretion (e.g. gastrectomy) * Twofold or more than upper limit of normal range in laboratory test for ALT or AST * Participating in other clinical trial study within 2 month preceding the first dose of investigational product * History of significant alcohol abuse or drug abuse within one year prior to the screening * Whole blood donation within 2 months prior to dosing, or apheresis donation within 1 month prior to dosing * Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study * Unwilling or unable to comply with the lifestyle guidelines described in this protocol * Subjects who are inadequate for this study to participate judged by investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AUCt(0-24) | First, fourth, fifth, and sixth day. At 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours post-dose in sixth day. (15 times) |
| Css,max | First, fourth, fifth, and sixth day. At 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours post-dose in sixth day. (15 times) |
Secondary
| Measure | Time frame |
|---|---|
| Tss,max | First, fourth, fifth, and sixth day. At 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours post-dose in sixth day. (15 times) |
| t1/2 | First, fourth, fifth, and sixth day. At 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours post-dose in sixth day. (15 times) |
| Css,min | First, fourth, fifth, and sixth day. At 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours post-dose in sixth day. (15 times) |
| Vd/F | First, fourth, fifth, and sixth day. At 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours post-dose in sixth day. (15 times) |
| CL/F | First, fourth, fifth, and sixth day. At 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours post-dose in sixth day. (15 times) |
| Css,av | First, fourth, fifth, and sixth day. At 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours post-dose in sixth day. (15 times) |
Countries
South Korea
Outcome results
None listed